含奥沙利铂化疗方案治疗晚期原发性肝细胞癌的研究进展

doi:10.3760/cma.j.issn.1673422X.2016.07.017

摘要/Abstract

摘要： 索拉非尼是目前唯一被多国批准的治疗晚期原发性肝细胞癌（HCC）的分子靶向药物，但其对生存期改善有限，最终出现病情进展。近几年，含奥沙利铂的化疗方案显示出良好的临床疗效，且患者耐受性可，为晚期HCC患者提供了新的治疗选择。

Abstract: Sorafenib is currently the only systematic molecular targeted drug approved by many countries for the treatment of advanced HCC. But sorafenib limites has survival improvement, patients appear inevitable disease progression soon. In recent years,Oxaliplatinbased regimens showed promising antitumor activity, safety and low toxicities, which provides a new way for treatment of advanced HCC.

Key words: Carcinoma, hepatocellular, Drug therapy, Oxaliplatin

宋迪迪, 刘传勇. 含奥沙利铂化疗方案治疗晚期原发性肝细胞癌的研究进展[J]. 国际肿瘤学杂志, 2016, 43(7): 545-547.

SONG Di-Di, LIU Chuan-Yong. Research progress of oxaliplatinbased regimen for advanced hepatocellular carcinoma[J]. Journal of International Oncology, 2016, 43(7): 545-547.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. DOI： 10.3322/caac.20107. ［2］ Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, doubleblind, placebocontrolled trial［J］. Lancet Oncol, 2009, 10(1): 2534. DOI： 10.1016/S14702045(08)702857. ［3］ Lv Y, Liang R, Hu X, et al. Combination of oxaliplatin and S1 versus sorafenib alone in patients with advanced hepatocellular carcinoma［J］. Pharmazie, 2014, 69(10): 759763. . ［4］ Petrelli F, Coinu A, Borgonovo K, et al. Oxaliplatinbased chemotherapy: a new option in advanced hepatocellular carcinoma. A systematic review and pooled analysis［J］. Clin Oncol (R Coll Radiol), 2014, 26(8): 488496. DOI： 10.1016/j.clon.2014.04.031. ［5］ Dhooge M, Coriat R, Mir O, et al. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with ChildPugh B cirrhosis［J］. Oncology, 2013, 84(1): 3238. DOI： 10.1159/000342763. ［6］ Qin SK, Bai YX, Lim HY, et al. Randomized, multicenter, openlabel study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia［J］. J Clin Oncol, 2013, 31(28): 35013508. DOI： 10.1200/JCO.2012.44.5643. ［7］ Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study［J］. J Hepatol, 2013, 58(1): 8188. DOI： 10.1016/j.jhep.2012.09.006. ［8］ Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase Ⅱ study［J］. Cancer, 2007, 109(7): 13841390. DOI： 10.1002/cncr.22532. ［9］ Mir O, Coriat R, BoudouRouquette P, et al. Gemcitabine and oxaliplatin as secondline treatment in patients with hepatocellular carcinoma pretreated with sorafenib［J］. Med Oncol, 2012, 29(4): 27932799. DOI: 10.1007/s120320120208x. ［10］ Patrikidou A, Sinapi I, Regnault H, et al. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of antiangiogenic therapies［J］. Invest New Drugs, 2014, 32(5): 10281035. DOI： 10.1007/s106370140100y. ［11］ Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study［J］. Cancer, 2008, 112(12): 27332739. DOI： 10.1002/cncr.23489. ［12］ Boige V, Raoul JL, Pignon JP, et al. Multicentre phase Ⅱ trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 0303 trial［J］. Br J Cancer, 2007, 97(7): 862867. DOI： 10.1038/sj.bjc.6603956. ［13］王锋, 秦叔逵, 华海清, 等. 含奥沙利铂化疗方案治疗对索拉非尼耐药的晚期原发性肝癌的临床观察［J］. 临床肿瘤学杂志, 2014, 3(3): 226230. ［14］ Sun W, Sohal D, Haller DG, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma［J］. Cancer, 2011, 117(14): 31873192. DOI： 10.1002/cncr.25889. ［15］ Sanoff HK, Bernard S, Goldberg RM, et al. Phase Ⅱ study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma［J］. Gastrointest Cancer Res, 2011, 4(3): 7883.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.